<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695483</url>
  </required_header>
  <id_info>
    <org_study_id>PE-PMA</org_study_id>
    <secondary_id>2020-004329-21</secondary_id>
    <nct_id>NCT04695483</nct_id>
  </id_info>
  <brief_title>Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial</brief_title>
  <acronym>PE-PMA</acronym>
  <official_title>Reduction of Progesterone Elevation at Trigger in Poor Responder Bologna' Criteria Patients After Controlled Ovarian Stimulation With Long Acting Standard Stimulation Protocol Compared With Conventional Daily Protocol: a Single Center Prospective Randomized Fase IV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching objective of this research is to generate clinical evidence to argue the&#xD;
      benefits of long acting stimulation protocol compared to the daily stimulation protocol in&#xD;
      poor ovarian responder bologna' criteria patients after controlled ovarian stimulation.&#xD;
      Reduction in the proportion of subjects with progesterone &gt; 1.1 ng/ml on the day of&#xD;
      triggering (day + 13) in the experimental group compared to the control group is expected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will receive a first visit for infertility where will be collected subject&#xD;
      history and baseline information, and meet all the inclusion / exclusion criteria. Eligible&#xD;
      patients who agreed to participate will be randomized to either long acting standard COS with&#xD;
      corifollitropin alpha or standard COS with daily FSH in a fixed GnRH antagonist protocol. All&#xD;
      patients will be allowed to participate in the study only once and a written informed consent&#xD;
      will be obtained from all, following consultation and before the initiation of the treatment.&#xD;
&#xD;
      The endocrine profile of all the patients will be evaluated by analysis of serum&#xD;
      progesterone, 17b-estradiol (E2), FSH and LH at different time points: basal condition,&#xD;
      during stimulation, at the hCG day and at pick-up.&#xD;
&#xD;
      Transvaginal follicular aspiration will be performed by ultrasound guidance 36 hours after&#xD;
      hCG administration. The day of pick up oocytes will be fertilized with partner's semen; after&#xD;
      3-5 days, on the base of its evolution, embryo will be transferred. 14 days after&#xD;
      embryo-transfer a preg-nancy test will be performed. Follow up in case of obtained pregnancy&#xD;
      will be done until 20 weeks of gestation and considered as ongoing pregnancy.&#xD;
&#xD;
      The entire duration of the study is 24 months, the follow up of the last patients enrolled&#xD;
      will be 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 7, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Premature progesterone elevation</measure>
    <time_frame>day 12</time_frame>
    <description>Progesterone &gt; or equal to 1.1 ng/mL at day of trigger</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of freeze-all cycles due to premature progesterone elevation</measure>
    <time_frame>day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes collected at ovum retrieval</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>day 15</time_frame>
    <description>Percentage of oocytes fertilized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos available</measure>
    <time_frame>Day 17</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>day 30</time_frame>
    <description>Beta-HCG positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Vital fetus at 20 weeks of gestation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Corifollitropin alpha group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FSH group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corifollitropin alfa</intervention_name>
    <description>Controlled ovarian stimulation long-acting protocol</description>
    <arm_group_label>Corifollitropin alpha group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin Beta</intervention_name>
    <description>Daily controlled ovarian stimulation protocol</description>
    <arm_group_label>Corifollitropin alpha group</arm_group_label>
    <arm_group_label>FSH group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication to IVF treatment&#xD;
&#xD;
          -  Normal BMI (18.5-24.9 kg/m2)&#xD;
&#xD;
          -  AMH level &lt; 1.1 ng/ml and/or AFC &lt; 5 follicles and/or &lt; 3 oo-cytes retrieved in&#xD;
             previous cycle&#xD;
&#xD;
          -  Regular menstrual cycles&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Freeze all cycles for abnormal bleeding&#xD;
&#xD;
          -  PCOS&#xD;
&#xD;
          -  History of untreated autoimmune&#xD;
&#xD;
          -  Endocrine or metabolic disorders&#xD;
&#xD;
          -  Ovarian cystectomy or oophorectomy&#xD;
&#xD;
          -  FSH â‰¥ 20 lU/L&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrico Papaleo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrico Papaleo, MD</last_name>
    <phone>+390226436228</phone>
    <email>papaleo.enrico@hsr.it</email>
  </overall_contact>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Enrico Papaleo</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

